Windtree Therapeutics Concludes Enrollment In Mid-Stage Cardiogenic Shock Study, Data Expected In April
Windtree Therapeutics Inc (NASDAQ: WINT) has completed enrollment in its phase 2 study of istaroxime in early cardiogenic shock caused by heart failure.
The study enrolled 60 patients with severe heart failure and systolic blood pressure (SBP) between 75 and 90 mmHg.
The study drug was administered over 24 hours. The primary endpoint is the SBP profile over the first 6 hours after initiating the infusion.
Secondary endpoints will include various assessments of blood pressure changes over 24 hours and measures associated with safety and tolerability.
All patients will complete a 30-day follow-up before database lock and generation of topline data.
Topline data is expected in April.
Cardiogenic shock is a condition that occurs when the heart is failing significantly and cannot pump enough blood and oxygen to the brain, kidneys, and other vital organs.
Istaroxime is a first-in-class, dual mechanism therapy designed to improve systolic and diastolic cardiac function.
Price Action: WINT shares are up 1.02% at $0.95 during the market session on the last check Tuesday.
See more from Benzinga
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
